Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 564,907,392
  • Shares Outstanding, K 2,409,295
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 30,897 M
  • EBITDA $ 38,236 M
  • 60-Month Beta 0.35
  • Price/Sales 5.96
  • Price/Cash Flow 17.76
  • Price/Book 7.08

Options Overview Details

View History
  • Implied Volatility 21.67% (+1.36%)
  • Historical Volatility 14.85%
  • IV Percentile 90%
  • IV Rank 40.70%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 8) 5.45 (2.29%)
  • Put/Call Vol Ratio 0.73
  • Today's Volume 28,147
  • Volume Avg (30-Day) 30,378
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 359,485
  • Open Int (30-Day) 379,676
  • Expected Range 232.34 to 243.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.68
  • Number of Estimates 8
  • High Estimate 2.85
  • Low Estimate 2.41
  • Prior Year 2.77
  • Growth Rate Est. (year over year) -3.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
203.85 +16.65%
on 01/12/26
239.58 -0.75%
on 02/05/26
+33.48 (+16.39%)
since 01/05/26
3-Month
185.12 +28.45%
on 11/10/25
239.58 -0.75%
on 02/05/26
+51.79 (+27.84%)
since 11/05/25
52-Week
141.50 +68.05%
on 04/09/25
239.58 -0.75%
on 02/05/26
+83.10 (+53.72%)
since 02/05/25

Most Recent Stories

More News
Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Johnson & Johnson (NYSE: JNJ) will present at the TD Cowen 46 th Annual Health Care Conference on Tuesday, March 3 rd , 2026. Management will participate...

JNJ : 237.79 (+1.42%)
What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

XLV : 154.84 (-0.76%)
$SPX : 6,798.40 (-1.23%)
JNJ : 237.79 (+1.42%)
1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

$SPX : 6,798.40 (-1.23%)
JNJ : 237.79 (+1.42%)
KVUE : 18.07 (+0.33%)
Kenvue Is Headed for a Merger Vote on January 29. How Should You Play KVUE Stock Here?

KVUE stock could gain 15% this week if the potential merger with Kimberly-Clark is approved by all major stakeholders.

KMB : 104.26 (+1.02%)
JNJ : 237.79 (+1.42%)
KVUE : 18.07 (+0.33%)
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care    

JNJ : 237.79 (+1.42%)
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

$20 million additional funding is planned for 2026 to support programs and impact investments that increase access to Cardiovascular, Surgery and Vision care Partnerships...

JNJ : 237.79 (+1.42%)
Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors

Healthcare stocks rebounded in 2025. These three healthcare growth stocks offer exposure to innovation beyond traditional biotech risk

EW : 78.10 (-2.09%)
JNJ : 237.79 (+1.42%)
ISRG : 476.32 (-0.45%)
IQV : 180.96 (-10.65%)
Johnson & Johnson Quietly Triggers a Trend Following Buy Signal

Johnson & Johnson is poised to advance in H2 2026 as growth, cash flow, and capital returns drive bullish analysts and institutional sentiment.

JNJ : 237.79 (+1.42%)
Johnson & Johnson’s Profit And Sales Top Estimates

Pharmaceutical company Johnson & Johnson (JNJ) has reported strong financial results for the fourth ...

JNJ : 237.79 (+1.42%)
Johnson & Johnson: Q4 Earnings Snapshot

Johnson & Johnson: Q4 Earnings Snapshot

JNJ : 237.79 (+1.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 244.51
2nd Resistance Point 242.04
1st Resistance Point 239.92
Last Price 237.79
1st Support Level 235.33
2nd Support Level 232.86
3rd Support Level 230.74

See More

52-Week High 239.58
Last Price 237.79
Fibonacci 61.8% 202.11
Fibonacci 50% 190.54
Fibonacci 38.2% 178.97
52-Week Low 141.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar